BDBM295666 (S)-2-cyclobutyl-2-((2-((R)-4- methyl-2-oxooxazolidin-3-yl)-5,6- dihydrobenzo[f]imidazo[1,2- d][1,4]oxazepin-9- yl)amino)acetamide::US10112932, Compound 102::US10851091, Compound 102
SMILES: C[C@@H]1COC(=O)N1c1cn2CCOc3cc(N[C@@H](C4CCC4)C(N)=O)ccc3-c2n1
InChI Key: InChIKey=XJWQCIXSLCHRNE-XIKOKIGWSA-N
Data: 8 KI
Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kcal/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (Homo sapiens (Human)) | BDBM295666 ((S)-2-cyclobutyl-2-((2-((R)-4- methyl-2-oxooxazoli...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 0.949 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Genentech, Inc. US Patent | Assay Description The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ... | US Patent US10851091 (2020) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
PI3-kinase class I (Homo sapiens (Human)) | BDBM295666 ((S)-2-cyclobutyl-2-((2-((R)-4- methyl-2-oxooxazoli...) | PDB UniProtKB/SwissProt UniProtKB/TrEMBL antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 0.949 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Genentech, Inc. US Patent | Assay Description PI3K Binding assays are intended for determining the biochemical potency of small molecule PI3K inhibitors. The PI3K lipid kinase reaction is perform... | US Patent US10112932 (2018) BindingDB Entry DOI: 10.7270/Q2JQ132B | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform (Homo sapiens (Human)) | BDBM295666 ((S)-2-cyclobutyl-2-((2-((R)-4- methyl-2-oxooxazoli...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 286 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Genentech, Inc. US Patent | Assay Description The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ... | US Patent US10851091 (2020) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform (Homo sapiens (Human)) | BDBM295666 ((S)-2-cyclobutyl-2-((2-((R)-4- methyl-2-oxooxazoli...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 286 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Genentech, Inc. US Patent | Assay Description PI3K Binding assays are intended for determining the biochemical potency of small molecule PI3K inhibitors. The PI3K lipid kinase reaction is perform... | US Patent US10112932 (2018) BindingDB Entry DOI: 10.7270/Q2JQ132B | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform (Homo sapiens (Human)) | BDBM295666 ((S)-2-cyclobutyl-2-((2-((R)-4- methyl-2-oxooxazoli...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 708 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Genentech, Inc. US Patent | Assay Description The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ... | US Patent US10851091 (2020) | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform (Homo sapiens (Human)) | BDBM295666 ((S)-2-cyclobutyl-2-((2-((R)-4- methyl-2-oxooxazoli...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 708 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Genentech, Inc. US Patent | Assay Description PI3K Binding assays are intended for determining the biochemical potency of small molecule PI3K inhibitors. The PI3K lipid kinase reaction is perform... | US Patent US10112932 (2018) BindingDB Entry DOI: 10.7270/Q2JQ132B | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Phosphatidylinositol 3-kinase regulatory subunit beta (Homo sapiens (Human)) | BDBM295666 ((S)-2-cyclobutyl-2-((2-((R)-4- methyl-2-oxooxazoli...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | >1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Genentech, Inc. US Patent | Assay Description PI3K Binding assays are intended for determining the biochemical potency of small molecule PI3K inhibitors. The PI3K lipid kinase reaction is perform... | US Patent US10112932 (2018) BindingDB Entry DOI: 10.7270/Q2JQ132B | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform (Homo sapiens (Human)) | BDBM295666 ((S)-2-cyclobutyl-2-((2-((R)-4- methyl-2-oxooxazoli...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | >1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Genentech, Inc. US Patent | Assay Description The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ... | US Patent US10851091 (2020) | |||||||||||
More data for this Ligand-Target Pair |